What Is Prostate Cancer? A Plain-English Overview

Prostate cancer happens when cells inside the prostate gland start growing and dividing abnormally, forming a tumor. It's the second most common cancer in men worldwide (after skin cancer) and the most common cancer in men in the US — roughly 1 in 8 men will be diagnosed in their lifetime. Unlike many cancers, most prostate cancer grows slowly, and the large majority of men diagnosed today survive it.

Is a Prostate Cancer Diagnosis as Scary as It Sounds? Short Answer

For the majority of men, no — and understanding why is genuinely important for anyone newly facing this diagnosis or worried about the possibility. Prostate cancer occupies a unique position among cancers: it's extremely common (1 in 8 men over a lifetime) but disproportionately survivable, with localized disease carrying a 5-year relative survival rate above 99%. This isn't because prostate cancer is inherently 'not real' cancer — it's a genuine malignancy — but because most cases are caught while still confined to the gland and grow slowly enough that aggressive immediate treatment often isn't even necessary, with active surveillance being a legitimate, evidence-backed path for many low-risk diagnoses rather than a compromise. The word 'cancer' understandably triggers alarm, but a prostate cancer diagnosis today, especially one caught through routine screening at an early, localized stage, carries a fundamentally different prognosis than the word evokes for many other cancers. The genuinely serious cases — higher-grade disease or cancer caught after it has spread beyond the gland — are a real minority of diagnoses, which is exactly why grading and staging (covered below) matter more for understanding your actual outlook than the diagnosis label alone.

How Prostate Cancer Develops

Prostate cancer almost always starts in the gland cells that produce prostatic fluid. Genetic mutations — some inherited, some accumulated with age — cause these cells to grow uncontrollably. Most prostate cancer is adenocarcinoma, meaning it starts in gland tissue rather than muscle or connective tissue. It typically begins in the outer (peripheral) zone of the prostate, which is one reason a digital rectal exam can sometimes detect it even when PSA is normal.

Is Prostate Cancer Serious?

It depends heavily on the grade and stage at diagnosis. Localized prostate cancer (still confined to the prostate) has a 5-year relative survival rate above 99%. Even regional-stage disease has excellent outcomes. The picture changes for distant/metastatic disease, where survival drops substantially — which is exactly why early detection through PSA screening matters so much. This is also why prostate cancer is often described as one of the more "manageable" cancers when caught early, and one of the more dangerous ones when caught late.

Prostate Cancer vs. BPH

It's easy to confuse the two because they cause similar urinary symptoms and both become more common with age — but they're unrelated processes. BPH (enlarged prostate) is benign cell overgrowth; prostate cancer is malignant. You can have one, both, or neither. See our prostate cancer vs. BPH comparison for how to tell symptoms apart — though the honest answer is you usually can't, without testing.

What Happens After Diagnosis

• •Grading (Gleason Score / Grade Group) — how aggressive the cancer looks under a microscope
• •Staging — how far it has spread, from confined-to-prostate to distant metastasis
• •Treatment planning — ranging from active surveillance for low-risk disease to surgery, radiation, or hormone therapy for higher-risk disease

For a full breakdown of options, see our complete guide to prostate cancer treatment and Gleason score explained.

How Common Is Prostate Cancer, Really?

Prostate cancer is diagnosed in roughly 1 in 8 men over a lifetime, making it the most common non-skin cancer in men. But incidence and mortality tell very different stories: while a large share of men will develop some form of prostate cancer if they live long enough, only a small fraction will die from it. Autopsy studies have repeatedly found undiagnosed, low-grade prostate cancer in a large percentage of older men who died of unrelated causes — meaning many men live and die with prostate cancer, not from it. This is the central reason active surveillance exists as a legitimate treatment path for low-risk disease, rather than immediate aggressive treatment for every diagnosis.

What Raises the Risk

• •Age — risk rises sharply after 50, and most cases are diagnosed after 65
• •Family history — having a father or brother with prostate cancer roughly doubles risk
• •Race — Black men have both higher incidence and higher mortality, for reasons still being researched
• •Genetic mutations — BRCA1/BRCA2 (yes, the same genes linked to breast cancer) and Lynch syndrome raise risk
• •Diet and lifestyle — high saturated fat intake and obesity are linked to more aggressive disease, though the evidence is less definitive than for the factors above

See our full prostate cancer risk factors guide for how these combine to determine when screening should start — often earlier than 50 for men with a family history or who are Black.

How Prostate Cancer Is Actually Found

Most prostate cancer is found one of two ways: an elevated or rising PSA blood test prompting further workup, or an abnormal finding on a digital rectal exam. Neither test diagnoses cancer by itself — an abnormal result typically leads to an MRI and, if the MRI shows a suspicious area, a needle biopsy, which is the only way to confirm a diagnosis and assign a Gleason score. Because early prostate cancer usually causes no symptoms at all, screening (not symptom-watching) is what catches it early — see our PSA screening decision guide for the actual guidelines and tradeoffs.

Why Autopsy Studies Change How Doctors Think About Prostate Cancer

One of the more striking findings in prostate cancer research comes from autopsy studies of men who died of unrelated causes — car accidents, heart disease, other conditions entirely — where researchers found undiagnosed, low-grade prostate cancer present in a substantial share of these men, particularly older men, despite the cancer never having caused symptoms or been detected during their lifetime. This finding fundamentally reshaped how the medical field thinks about prostate cancer: it revealed that a meaningful proportion of prostate cancer is biologically indolent enough that it would never have become clinically significant if left entirely undetected and untreated. This is precisely the scientific basis for active surveillance as a legitimate management strategy for low-risk, low-grade disease — rather than treating every diagnosis identically with immediate aggressive intervention, modern prostate cancer care increasingly distinguishes between cancer that needs treating now and cancer that can be safely monitored, sparing many men from the real side effects of surgery or radiation for a disease that may never have threatened their health or lifespan.